JAMIE KARRH: Open Payments
NPI 1992455661 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,065 in 49 payments from 10 companies in 2025. Trend: 2023 $1,499 · 2024 $1,254 · 2025 $1,065
Food & beverage: $1,065
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 18 | $285 |
| Vanda Pharmaceuticals Inc. | 4 | $199 |
| Teva Pharmaceuticals USA, Inc. | 9 | $156 |
| Neurocrine BioSciences, Inc. | 4 | $129 |
| Otsuka America Pharmaceutical, Inc. | 3 | $83 |
| ABBVIE INC. | 4 | $72 |
| Alkermes, Inc. | 3 | $70 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: COBENFY, FANAPT, INGREZZA, UZEDY, ABILIFY ASIMTUFII, VRAYLAR, ARISTADA, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
